Literature DB >> 10697265

Value of the mesothelium-associated antibodies thrombomodulin, cytokeratin 5/6, calretinin, and CD44H in distinguishing epithelioid pleural mesothelioma from adenocarcinoma metastatic to the pleura.

P M Cury1, D N Butcher, C Fisher, B Corrin, A G Nicholson.   

Abstract

Until recently, the standard approach of most laboratories in distinguishing epithelioid pleural mesothelioma from metastatic adenocarcinoma has been a negative result from a panel of adenocarcinoma-associated antibodies. However, several "mesothelium-associated" antibodies have been proposed as useful in this situation, and we have applied four of these putative mesothelioma markers--thrombomodulin, cytokeratin 5/6, calretinin, and CD44H--to a series of 61 epithelioid pleural mesotheliomas and 63 metastatic adenocarcinomas with known primary sites (lung = 19; breast = 21; ovary = 6; colon = 10; kidney = 4; uterus, epididymis, pancreas = 1 case each). Of the mesotheliomas, 55 of 61 (90%) stained for thrombomodulin, 56 of 61 (92%) for cytokeratin 5/6, 47 of 51 cases (92%) were positive for calretinin, and 39 of 43 (91%) were positive for CD44H. Of the metastatic adenocarcinomas, 12 of 63 (19%) cases were positive for thrombomodulin, 9 of 63 (14%) were positive for CK5/6, and 27 of 60 (45%) were positive for CD44H. With calretinin, only 1 case of 59 (2%) showed positive nuclear staining. All four antibodies stained reactive mesothelium; thrombomodulin also stained endothelium; and CD44H variably stained lymphocytes, macrophages, and fibroblasts. We conclude that all four antibodies show high sensitivity for epithelioid mesothelioma, but only calretinin (98%), cytokeratin 5/6 (86%), and thrombomodulin (81%) show sufficient specificity for practical use in this situation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10697265     DOI: 10.1038/modpathol.3880018

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  17 in total

1.  Recommendations for the reporting of pleural mesothelioma.

Authors:  Kelly J Butnor; Thomas A Sporn; Nelson G Ordonez
Journal:  Virchows Arch       Date:  2006-11-25       Impact factor: 4.064

2.  [Plasmacytoid carcinoma. Five case reports of a rare variant of urothelial carcinoma].

Authors:  B Keck; R Stöhr; P J Goebell; H M Fritsche; B Wullich; A Hartmann
Journal:  Pathologe       Date:  2008-09       Impact factor: 1.011

3.  My approach to the diagnosis of mesothelial lesions.

Authors:  K J Butnor
Journal:  J Clin Pathol       Date:  2006-06       Impact factor: 3.411

Review 4.  Adenocarcinoma cells in effusion cytology as a diagnostic pitfall with potential impact on clinical management: a case report with brief review of immunomarkers.

Authors:  Sinchita Roy Chowdhuri; Patricia Fetsch; Jennifer Squires; Elise Kohn; Armando C Filie
Journal:  Diagn Cytopathol       Date:  2012-11-16       Impact factor: 1.582

Review 5.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

6.  Spindle cell tumours of the pleura: a clinical, histological and comparative genomic hybridization analysis of 14 cases.

Authors:  Aija Knuuttila; Kowan J Jee; Eero Taskinen; Henrik Wolff; Sakari Knuutila; Sisko Anttila
Journal:  Virchows Arch       Date:  2005-09-17       Impact factor: 4.064

7.  Malignant mesothelioma: a comparison of biopsy and postmortem material by light microscopy and immunohistochemistry.

Authors:  F Roberts; A E McCall; R A Burnett
Journal:  J Clin Pathol       Date:  2001-10       Impact factor: 3.411

8.  Distribution of p63, cytokeratins 5/6 and cytokeratin 14 in 51 normal and 400 neoplastic human tissue samples using TARP-4 multi-tumor tissue microarray.

Authors:  Jorge S Reis-Filho; Pete T Simpson; Albino Martins; Ana Preto; Fátima Gärtner; Fernando C Schmitt
Journal:  Virchows Arch       Date:  2003-07-16       Impact factor: 4.064

9.  Specificity of MOC-31 and HBME-1 immunohistochemistry in the differential diagnosis of adenocarcinoma and malignant mesothelioma: a study on environmental malignant mesothelioma cases from Turkish villages.

Authors:  Derya Gümürdülü; E Handan Zeren; Philip T Cagle; Fazilet Kayasel uk; Nazan Alparslan; Ali Kocabas; Ilhan Tuncer
Journal:  Pathol Oncol Res       Date:  2003-01-06       Impact factor: 3.201

10.  Certified causes of death in patients with mesothelioma in South East England.

Authors:  Catherine Okello; Tom Treasure; Andrew G Nicholson; Julian Peto; Henrik Møller
Journal:  BMC Cancer       Date:  2009-01-23       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.